Anti-CD3 anti-CD20 bispecific antibody - Genmab

Drug Profile

Anti-CD3 anti-CD20 bispecific antibody - Genmab

Alternative Names: Duobody-CD3-CD20; DuoBody-CD3xCD20

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; CD3 antigen inhibitors; CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies

Most Recent Events

  • 01 Jan 2018 Phase-I/II clinical trials in Haematological malignancies in Denmark (Parenteral) (Genmab pipeline, January 2018)
  • 08 Jan 2016 Genmab has patents pending for anti-CD3 anti-CD20 bispecific antibodies worldwide, including Canada and Europe Union
  • 01 Jan 2016 Preclinical clinical trials in Haematological malignancies in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top